Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
NCT05344833
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is looking at a new treatment for patients who have a certain kind of cancer and have already had a stem cell transplant. If the patients still have a small amount of cancer in their body after the transplant, they will get a drug called isatuximab and another drug called lenalidomide to help get rid of the remaining cancer.
This study is looking at a new treatment for patients who have a certain kind of cancer and have already had a stem cell transplant. If the patients still have a small amount of cancer in their body after the transplant, they will get a drug called isatuximab and another drug called lenalidomide to help get rid of the remaining cancer.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
